A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2)
Real World EviDEnce of the EffecTIveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents 12 to <18 Years of Age With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Chelyabinsk, Russian Federation, 454048
- South-Ural Medical State University /ID# 218501
-
Ekaterinburg, Russian Federation, 620102
- Sverdlovsk Regional Center of AIDS Prevention and Control /ID# 222253
-
Irkutsk, Russian Federation, 664035
- Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 222252
-
Moscow, Russian Federation, 115093
- Children's Clinical Multidisciplinary Center of the Moscow Region /ID# 226590
-
Moscow, Russian Federation, 125310
- Infectious Clinical Hosp #1 /ID# 218497
-
Samara, Russian Federation, 443029
- Samara Region Clinical HIV/AIDS Prevention and Control Center /ID# 218499
-
-
Dagestan, Respublika
-
Makhachkala, Dagestan, Respublika, Russian Federation, 367000
- Dagestan State Medical University /ID# 218500
-
-
Tatarstan, Respublika
-
Kazan, Tatarstan, Respublika, Russian Federation, 420140
- A.F.Agafonov Republican Clinical Infectious Hospital /ID# 218498
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed diagnosis of chronic hepatitis C (CHC) with genotypes 1, 2, 3, 4, 5 or 6 with or without compensated cirrhosis
- Treatment naive or treatment experienced participants
- Receiving combination therapy with the all oral GLE/PIB regimen according to standard of care, international guidelines with the current local label
- Participant and his/her legal representative voluntarily signs and dates an informed consent form
- Must not be participating or intending to participant in a concurrent interventional therapeutic trial
Exclusion Criteria:
None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Participants Treated with GLE/PIB
Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study.
Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Percentage of Participants Achieving Sustained Viral Response 12 (SVR12)
Time Frame: At Week 12
|
Defined as HCV RNA <50 IU/mL or <lower limit of qualification/detection (LLoQ/D) at the site 12 weeks after the last actual dose of GLE/PIB.
|
At Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving Sustained Viral Response 12 (SVR12) With a Sensitive Polymerase Chain Reaction (PCR) Available in the Clinical Site
Time Frame: At Week 12
|
Defined as HCV RNA <50 IU/mL or <lower limit of qualification/detection (LLoQ/D) at the stie 12 weeks after the last actual dose of GLE/PIB.
|
At Week 12
|
|
Number of Participants With Co-morbidities
Time Frame: At Baseline Visit (Week 0)
|
Number and percentage of participants with co-morbidities will be analyzed.
|
At Baseline Visit (Week 0)
|
|
Number of Participants Taking Concomitant Medications
Time Frame: Up to approximately 28 weeks
|
Number and percentage of participants taking concomitant medications will be analyzed.
|
Up to approximately 28 weeks
|
|
Percentage of GLE/PIB Dose Taken by Participants in Relation to the Prescribed Target Dose
Time Frame: Up to approximately 16 weeks
|
Percentage of GLE/PIB pills taken out of the number that was prescribed.
|
Up to approximately 16 weeks
|
|
Number of Participants with Adverse Events
Time Frame: Up to approximately 28 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
|
Up to approximately 28 weeks
|
|
Average Number of Visits/Touch Points as Part of Health Care Resource Utilization (HCRU)
Time Frame: Up to approximately 28 weeks
|
Health Care Resource Utilization (HCRU) for a participant will be the total number of visits/touchpoints (face to face or phone call ) with a health care provider or designee in relation to their HCV infection during the study as recorded on an electronic case report form (eCRF).
|
Up to approximately 28 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
Other Study ID Numbers
Other Study ID Numbers
- P20-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.